HRP940481A2 - Iontophoretic delivery of an antimigrene drug - Google Patents

Iontophoretic delivery of an antimigrene drug Download PDF

Info

Publication number: HRP940481A2
Authority: HR; Croatia
Prior art keywords: formula; hydrogen; drug; bivalent; radical
Prior art date: 1993-08-27

Application number

HR93.202.523.2A

Other languages

English (en)

Croatian (hr)

Inventor

Jean Louis Mesens

Gustaaf Van Reet

Frank Maria Jozef De Beukelaar

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-08-27

Filing date

1994-08-26

Publication date

1997-08-31

1994-08-26 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

1997-08-31 Publication of HRP940481A2 publication Critical patent/HRP940481A2/hr

Links

239000003814 drug Substances 0.000 title description 44
229940079593 drug Drugs 0.000 title description 42
150000001875 compounds Chemical class 0.000 claims abstract description 46
239000001257 hydrogen Substances 0.000 claims abstract description 24
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 24
150000003839 salts Chemical class 0.000 claims abstract description 18
239000002253 acid Substances 0.000 claims abstract description 14
150000002431 hydrogen Chemical group 0.000 claims abstract description 10
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 9
208000019695 Migraine disease Diseases 0.000 claims abstract description 9
206010027599 migraine Diseases 0.000 claims abstract description 9
101100490437 Mus musculus Acvrl1 gene Proteins 0.000 claims abstract description 4
125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 3
125000004356 hydroxy functional group Chemical group O* 0.000 claims abstract description 3
125000001475 halogen functional group Chemical group 0.000 claims abstract 2
-1 3,4-dihydro-2H-1-benzopyran-2-yl Chemical group 0.000 claims description 40
239000004480 active ingredient Substances 0.000 claims description 18
239000000463 material Substances 0.000 claims description 9
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
229910052709 silver Inorganic materials 0.000 claims description 8
239000004332 silver Substances 0.000 claims description 8
125000000217 alkyl group Chemical group 0.000 claims description 7
238000001647 drug administration Methods 0.000 claims description 7
229910021607 Silver chloride Inorganic materials 0.000 claims description 6
239000011159 matrix material Substances 0.000 claims description 6
HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 claims description 6
125000003342 alkenyl group Chemical group 0.000 claims description 5
125000000304 alkynyl group Chemical group 0.000 claims description 4
239000007788 liquid Substances 0.000 claims description 4
239000012528 membrane Substances 0.000 claims description 4
125000003545 alkoxy group Chemical group 0.000 claims description 2
239000007787 solid Substances 0.000 claims 2
125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
239000000203 mixture Substances 0.000 abstract description 20
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract description 10
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract description 5
150000002357 guanidines Chemical class 0.000 abstract description 2
210000003491 skin Anatomy 0.000 description 12
150000003254 radicals Chemical class 0.000 description 10
239000000243 solution Substances 0.000 description 9
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
239000000872 buffer Substances 0.000 description 8
238000000034 method Methods 0.000 description 8
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 8
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
239000003795 chemical substances by application Substances 0.000 description 7
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 6
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 6
229920001296 polysiloxane Polymers 0.000 description 6
125000004432 carbon atom Chemical group C* 0.000 description 5
230000005611 electricity Effects 0.000 description 5
239000002904 solvent Substances 0.000 description 5
239000008280 blood Substances 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000007853 buffer solution Substances 0.000 description 4
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
229930195733 hydrocarbon Natural products 0.000 description 4
229910052751 metal Inorganic materials 0.000 description 4
239000002184 metal Substances 0.000 description 4
229910052697 platinum Inorganic materials 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
239000004698 Polyethylene Substances 0.000 description 3
239000004743 Polypropylene Substances 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
235000010443 alginic acid Nutrition 0.000 description 3
229920000615 alginic acid Chemical class 0.000 description 3
229940124433 antimigraine drug Drugs 0.000 description 3
238000012377 drug delivery Methods 0.000 description 3
230000005684 electric field Effects 0.000 description 3
125000005843 halogen group Chemical group 0.000 description 3
239000012982 microporous membrane Substances 0.000 description 3
229920000573 polyethylene Polymers 0.000 description 3
229920001155 polypropylene Polymers 0.000 description 3
229920002635 polyurethane Polymers 0.000 description 3
239000004814 polyurethane Substances 0.000 description 3
229930195734 saturated hydrocarbon Natural products 0.000 description 3
229920001059 synthetic polymer Chemical class 0.000 description 3
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Natural products CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
239000004215 Carbon black (E152) Substances 0.000 description 2
244000303965 Cyamopsis psoralioides Species 0.000 description 2
206010019233 Headaches Diseases 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
229920000881 Modified starch Polymers 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
208000002193 Pain Diseases 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
235000010323 ascorbic acid Nutrition 0.000 description 2
150000001721 carbon Chemical group 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
150000004649 carbonic acid derivatives Chemical class 0.000 description 2
150000003841 chloride salts Chemical class 0.000 description 2
239000007979 citrate buffer Substances 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
230000002349 favourable effect Effects 0.000 description 2
229910052731 fluorine Inorganic materials 0.000 description 2
239000011737 fluorine Substances 0.000 description 2
239000006260 foam Substances 0.000 description 2
230000002440 hepatic effect Effects 0.000 description 2
150000002430 hydrocarbons Chemical class 0.000 description 2
239000000017 hydrogel Substances 0.000 description 2
229910052500 inorganic mineral Inorganic materials 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
239000011707 mineral Chemical class 0.000 description 2
235000010755 mineral Nutrition 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
235000019426 modified starch Nutrition 0.000 description 2
150000002823 nitrates Chemical class 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
125000004433 nitrogen atom Chemical group N* 0.000 description 2
239000012811 non-conductive material Substances 0.000 description 2
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
235000021317 phosphate Nutrition 0.000 description 2
235000011007 phosphoric acid Nutrition 0.000 description 2
150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
239000000419 plant extract Substances 0.000 description 2
239000004854 plant resin Substances 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
229920001184 polypeptide Chemical class 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
150000004804 polysaccharides Chemical class 0.000 description 2
108090000765 processed proteins & peptides Chemical class 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
238000003127 radioimmunoassay Methods 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
210000000434 stratum corneum Anatomy 0.000 description 2
150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
CUJPFPXNDSIBPG-UHFFFAOYSA-N 1,3-propanediyl Chemical group [CH2]C[CH2] CUJPFPXNDSIBPG-UHFFFAOYSA-N 0.000 description 1
ARIWANIATODDMH-AWEZNQCLSA-N 1-lauroyl-sn-glycerol Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)CO ARIWANIATODDMH-AWEZNQCLSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
NZJXADCEESMBPW-UHFFFAOYSA-N 1-methylsulfinyldecane Chemical compound CCCCCCCCCCS(C)=O NZJXADCEESMBPW-UHFFFAOYSA-N 0.000 description 1
125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
125000006024 2-pentenyl group Chemical group 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
229920000049 Carbon (fiber) Polymers 0.000 description 1
240000008886 Ceratonia siliqua Species 0.000 description 1
235000013912 Ceratonia siliqua Nutrition 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
241000206672 Gelidium Species 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010021518 Impaired gastric emptying Diseases 0.000 description 1
150000000994 L-ascorbates Chemical class 0.000 description 1
ARIWANIATODDMH-UHFFFAOYSA-N Lauric acid monoglyceride Natural products CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
MMOXZBCLCQITDF-UHFFFAOYSA-N N,N-diethyl-m-toluamide Chemical compound CCN(CC)C(=O)C1=CC=CC(C)=C1 MMOXZBCLCQITDF-UHFFFAOYSA-N 0.000 description 1
BDYUSDIJIDGWCY-UHFFFAOYSA-N NN-Dimethyllauramide Chemical compound CCCCCCCCCCCC(=O)N(C)C BDYUSDIJIDGWCY-UHFFFAOYSA-N 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
244000134552 Plantago ovata Species 0.000 description 1
235000003421 Plantago ovata Nutrition 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
229920002367 Polyisobutene Polymers 0.000 description 1
229920005830 Polyurethane Foam Polymers 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
239000009223 Psyllium Substances 0.000 description 1
206010040880 Skin irritation Diseases 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000015125 Sterculia urens Nutrition 0.000 description 1
240000001058 Sterculia urens Species 0.000 description 1
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
229920002494 Zein Polymers 0.000 description 1
108010055615 Zein Proteins 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
230000001270 agonistic effect Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
239000003513 alkali Substances 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
229920013820 alkyl cellulose Polymers 0.000 description 1
230000007815 allergy Effects 0.000 description 1
QVSXOXCYXPQXMF-UHFFFAOYSA-N alniditan Chemical compound C1CC2=CC=CC=C2OC1CNCCCNC1=NCCCN1 QVSXOXCYXPQXMF-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
229940009868 aluminum magnesium silicate Drugs 0.000 description 1
WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
230000002460 anti-migrenic effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
229940072107 ascorbate Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
239000002585 base Substances 0.000 description 1
239000000440 bentonite Substances 0.000 description 1
229910000278 bentonite Inorganic materials 0.000 description 1
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
238000009530 blood pressure measurement Methods 0.000 description 1
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
239000004327 boric acid Substances 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000004917 carbon fiber Substances 0.000 description 1
235000010418 carrageenan Nutrition 0.000 description 1
239000000679 carrageenan Substances 0.000 description 1
229920001525 carrageenan Polymers 0.000 description 1
229940113118 carrageenan Drugs 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
229920003086 cellulose ether Polymers 0.000 description 1
WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
239000000460 chlorine Chemical group 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
WLNARFZDISHUGS-MIXBDBMTSA-N cholesteryl hemisuccinate Chemical compound C1C=C2C[C@@H](OC(=O)CCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 WLNARFZDISHUGS-MIXBDBMTSA-N 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
229910052804 chromium Inorganic materials 0.000 description 1
239000011651 chromium Substances 0.000 description 1
150000001860 citric acid derivatives Chemical class 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
229940075614 colloidal silicon dioxide Drugs 0.000 description 1
230000002301 combined effect Effects 0.000 description 1
229920001940 conductive polymer Polymers 0.000 description 1
239000004020 conductor Substances 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
229960001673 diethyltoluamide Drugs 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
230000001079 digestive effect Effects 0.000 description 1
235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
YHAIUSTWZPMYGG-UHFFFAOYSA-L disodium;2,2-dioctyl-3-sulfobutanedioate Chemical compound [Na+].[Na+].CCCCCCCCC(C([O-])=O)(C(C([O-])=O)S(O)(=O)=O)CCCCCCCC YHAIUSTWZPMYGG-UHFFFAOYSA-L 0.000 description 1
GVGUFUZHNYFZLC-UHFFFAOYSA-N dodecyl benzenesulfonate;sodium Chemical compound [Na].CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 GVGUFUZHNYFZLC-UHFFFAOYSA-N 0.000 description 1
SYELZBGXAIXKHU-UHFFFAOYSA-N dodecyldimethylamine N-oxide Chemical compound CCCCCCCCCCCC[N+](C)(C)[O-] SYELZBGXAIXKHU-UHFFFAOYSA-N 0.000 description 1
230000000857 drug effect Effects 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000005370 electroosmosis Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
230000029142 excretion Effects 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
230000004907 flux Effects 0.000 description 1
239000011888 foil Substances 0.000 description 1
210000000245 forearm Anatomy 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000001640 fractional crystallisation Methods 0.000 description 1
239000012458 free base Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
208000001288 gastroparesis Diseases 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
229910002804 graphite Inorganic materials 0.000 description 1
239000010439 graphite Substances 0.000 description 1
159000000011 group IA salts Chemical class 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
KWLMIXQRALPRBC-UHFFFAOYSA-L hectorite Chemical compound [Li+].[OH-].[OH-].[Na+].[Mg+2].O1[Si]2([O-])O[Si]1([O-])O[Si]([O-])(O1)O[Si]1([O-])O2 KWLMIXQRALPRBC-UHFFFAOYSA-L 0.000 description 1
229910000271 hectorite Inorganic materials 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000003906 humectant Substances 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
239000011630 iodine Chemical group 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
239000011133 lead Substances 0.000 description 1
239000003446 ligand Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
239000000391 magnesium silicate Substances 0.000 description 1
229910052919 magnesium silicate Inorganic materials 0.000 description 1
235000019792 magnesium silicate Nutrition 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
VLCAYQIMSMPEBW-UHFFFAOYSA-N methyl 3-hydroxy-2-methylidenebutanoate Chemical compound COC(=O)C(=C)C(C)O VLCAYQIMSMPEBW-UHFFFAOYSA-N 0.000 description 1
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
QVSXOXCYXPQXMF-OAHLLOKOSA-N n-[[(2r)-3,4-dihydro-2h-chromen-2-yl]methyl]-n'-(1,4,5,6-tetrahydropyrimidin-2-yl)propane-1,3-diamine Chemical compound C([C@@H]1OC2=CC=CC=C2CC1)NCCCNC1=NCCCN1 QVSXOXCYXPQXMF-OAHLLOKOSA-N 0.000 description 1
GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
230000008693 nausea Effects 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
230000035515 penetration Effects 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
150000003016 phosphoric acids Chemical class 0.000 description 1
239000006187 pill Substances 0.000 description 1
239000010773 plant oil Substances 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
239000004584 polyacrylic acid Substances 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
229920001195 polyisoprene Polymers 0.000 description 1
239000002861 polymer material Substances 0.000 description 1
239000011496 polyurethane foam Substances 0.000 description 1
229920002689 polyvinyl acetate Polymers 0.000 description 1
239000011118 polyvinyl acetate Substances 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
239000011148 porous material Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
239000001294 propane Substances 0.000 description 1
235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
239000000770 propane-1,2-diol alginate Substances 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229940070687 psyllium Drugs 0.000 description 1
150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000003542 rubefacient Substances 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
230000036556 skin irritation Effects 0.000 description 1
231100000475 skin irritation Toxicity 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
229940080236 sodium cetyl sulfate Drugs 0.000 description 1
229940080264 sodium dodecylbenzenesulfonate Drugs 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
ADWNFGORSPBALY-UHFFFAOYSA-M sodium;2-[dodecyl(methyl)amino]acetate Chemical compound [Na+].CCCCCCCCCCCCN(C)CC([O-])=O ADWNFGORSPBALY-UHFFFAOYSA-M 0.000 description 1
GGHPAKFFUZUEKL-UHFFFAOYSA-M sodium;hexadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCOS([O-])(=O)=O GGHPAKFFUZUEKL-UHFFFAOYSA-M 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
229940032147 starch Drugs 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000008719 thickening Effects 0.000 description 1
239000011135 tin Substances 0.000 description 1
229910052718 tin Inorganic materials 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
239000003871 white petrolatum Substances 0.000 description 1
239000005019 zein Substances 0.000 description 1
229940093612 zein Drugs 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Electrotherapy Devices (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)

HR93.202.523.2A 1993-08-27 1994-08-26 Iontophoretic delivery of an antimigrene drug HRP940481A2 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP93202523		1993-08-27

Publications (1)

Publication Number	Publication Date
HRP940481A2 true HRP940481A2 (en)	1997-08-31

Family

ID=8214068

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR93.202.523.2A HRP940481A2 (en)	1993-08-27	1994-08-26	Iontophoretic delivery of an antimigrene drug

Country Status (28)

Country	Link
US (1)	US5674871A (de)
EP (1)	EP0719138B1 (de)
JP (1)	JP2921987B2 (de)
KR (1)	KR100187632B1 (de)
CN (1)	CN1096857C (de)
AT (1)	ATE176591T1 (de)
AU (1)	AU687876B2 (de)
BR (1)	BR9407522A (de)
CA (1)	CA2168449A1 (de)
CZ (1)	CZ290473B6 (de)
DE (1)	DE69416522T2 (de)
DK (1)	DK0719138T3 (de)
ES (1)	ES2129668T3 (de)
FI (1)	FI960887A0 (de)
GR (1)	GR3029920T3 (de)
HR (1)	HRP940481A2 (de)
HU (1)	HUT75062A (de)
IL (1)	IL110784A (de)
MY (1)	MY111022A (de)
NO (1)	NO317628B1 (de)
NZ (1)	NZ273304A (de)
PH (1)	PH31437A (de)
PL (1)	PL176290B1 (de)
RU (1)	RU2166315C2 (de)
SG (1)	SG50469A1 (de)
SI (1)	SI9400333B (de)
WO (1)	WO1995005815A1 (de)
ZA (1)	ZA946533B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5853383A (en) *	1995-05-03	1998-12-29	Alza Corporation	Preparation for formulations for electrotransport drug delivery
US7137975B2 (en) *	2001-02-13	2006-11-21	Aciont, Inc.	Method for increasing the battery life of an alternating current iontophoresis device using a barrier-modifying agent
CA2443326A1 (en) *	2001-04-04	2002-10-17	Alza Corporation	Transdermal electrotransport delivery device including an antimicrobial compatible reservoir composition
WO2002089803A1 (fr) *	2001-05-07	2002-11-14	Sankyo Company, Limited	Composition d'ionophorese
JP4394444B2 (ja) *	2001-10-24	2010-01-06	パワーペーパーリミティド	活性物質の制御された皮膚内デリバリーのためのデバイス及び方法
ITMI20021200A1 (it) *	2002-06-03	2003-12-03	Gafitex S R L	Tessuto atto ad esplicare un effetto barriera contro campi magnetici ed elettromagnetici e/o effetti di metalloterapia
US8016811B2 (en) *	2003-10-24	2011-09-13	Altea Therapeutics Corporation	Method for transdermal delivery of permeant substances
US20050220439A1 (en) *	2004-03-19	2005-10-06	Carton Owen A	Interactive multimedia system and method
WO2007009462A2 (en) *	2005-07-15	2007-01-25	Region Hovedstaden V/Glostrup Hospital	Treatment of migraine and headaches
GB2430364A (en) *	2005-09-22	2007-03-28	Carl Ernest Alexander	Soft agar bolus for oral drug delivery
WO2007120747A2 (en) *	2006-04-13	2007-10-25	Nupathe Inc.	Transdermal methods and systems for the delivery of anti-migraine compounds
RU2352359C1 (ru) *	2007-10-24	2009-04-20	Общество с ограниченнной ответственностью "НПО Текстильпрогресс Инженерной Академии " (ООО "НПО Текстильпрогресс ИА")	Способ создания композиции для доставки лекарственного препарата в полости организма при заболеваниях

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4028125A1 (de) *	1990-01-17	1991-07-18	Klimke Markus	Applikationsvorrichtung fuer die geregelte dosierung verschiedener pharmakons mittels elektrischem strom zum perkutanen transport zur lokalen und systemischen therapie
JP3740549B2 (ja) *	1990-03-30	2006-02-01	アルザ・コーポレーション	イオン侵透療法による薬剤投与の装置と方法
SI9300097B (en) *	1992-02-27	2001-12-31	Janssen Pharmaceutica Nv	(benzodioxan, benzofuran or benzopyran) alkylamino) alkyl substituted guanidines

1994
- 1994-07-15 PH PH48643A patent/PH31437A/en unknown
- 1994-08-19 NZ NZ273304A patent/NZ273304A/en unknown
- 1994-08-19 EP EP94926855A patent/EP0719138B1/de not_active Expired - Lifetime
- 1994-08-19 DE DE69416522T patent/DE69416522T2/de not_active Expired - Fee Related
- 1994-08-19 WO PCT/EP1994/002764 patent/WO1995005815A1/en not_active Ceased
- 1994-08-19 DK DK94926855T patent/DK0719138T3/da active
- 1994-08-19 CA CA002168449A patent/CA2168449A1/en not_active Abandoned
- 1994-08-19 KR KR1019960700410A patent/KR100187632B1/ko not_active Expired - Fee Related
- 1994-08-19 PL PL94313255A patent/PL176290B1/pl not_active IP Right Cessation
- 1994-08-19 ES ES94926855T patent/ES2129668T3/es not_active Expired - Lifetime
- 1994-08-19 BR BR9407522A patent/BR9407522A/pt not_active Application Discontinuation
- 1994-08-19 US US08/586,700 patent/US5674871A/en not_active Expired - Fee Related
- 1994-08-19 RU RU96105930/14A patent/RU2166315C2/ru not_active IP Right Cessation
- 1994-08-19 CN CN94193196A patent/CN1096857C/zh not_active Expired - Fee Related
- 1994-08-19 AT AT94926855T patent/ATE176591T1/de not_active IP Right Cessation
- 1994-08-19 CZ CZ1996570A patent/CZ290473B6/cs not_active IP Right Cessation
- 1994-08-19 AU AU76542/94A patent/AU687876B2/en not_active Ceased
- 1994-08-19 HU HU9600471A patent/HUT75062A/hu unknown
- 1994-08-19 JP JP7507338A patent/JP2921987B2/ja not_active Expired - Fee Related
- 1994-08-19 SG SG1996002184A patent/SG50469A1/en unknown
- 1994-08-25 MY MYPI94002234A patent/MY111022A/en unknown
- 1994-08-25 IL IL11078494A patent/IL110784A/xx not_active IP Right Cessation
- 1994-08-26 SI SI9400333A patent/SI9400333B/sl not_active IP Right Cessation
- 1994-08-26 HR HR93.202.523.2A patent/HRP940481A2/hr not_active Application Discontinuation
- 1994-08-26 ZA ZA946533A patent/ZA946533B/xx unknown
1996
- 1996-02-26 FI FI960887A patent/FI960887A0/fi not_active Application Discontinuation
- 1996-02-26 NO NO19960769A patent/NO317628B1/no unknown
1999
- 1999-04-07 GR GR990401012T patent/GR3029920T3/el unknown

Also Published As

Publication number	Publication date
CN1129905A (zh)	1996-08-28
DE69416522D1 (de)	1999-03-25
DK0719138T3 (da)	1999-09-20
CZ290473B6 (cs)	2002-07-17
SG50469A1 (en)	1998-07-20
FI960887A7 (fi)	1996-02-26
ZA946533B (en)	1996-02-26
GR3029920T3 (en)	1999-07-30
US5674871A (en)	1997-10-07
JP2921987B2 (ja)	1999-07-19
BR9407522A (pt)	1997-01-07
WO1995005815A1 (en)	1995-03-02
AU687876B2 (en)	1998-03-05
SI9400333B (sl)	2002-02-28
PL313255A1 (en)	1996-06-24
ATE176591T1 (de)	1999-02-15
SI9400333A (en)	1995-04-30
NO960769D0 (no)	1996-02-26
IL110784A (en)	1999-05-09
DE69416522T2 (de)	1999-09-23
NO960769L (no)	1996-04-23
CA2168449A1 (en)	1995-03-02
JPH09501180A (ja)	1997-02-04
IL110784A0 (en)	1994-11-11
FI960887A0 (fi)	1996-02-26
ES2129668T3 (es)	1999-06-16
RU2166315C2 (ru)	2001-05-10
HU9600471D0 (en)	1996-04-29
EP0719138B1 (de)	1999-02-10
CZ57096A3 (en)	1996-08-14
KR100187632B1 (ko)	1999-06-01
MY111022A (en)	1999-07-31
AU7654294A (en)	1995-03-21
NZ273304A (en)	1997-02-24
CN1096857C (zh)	2002-12-25
HUT75062A (en)	1997-03-28
EP0719138A1 (de)	1996-07-03
PL176290B1 (pl)	1999-05-31
PH31437A (en)	1998-11-03
NO317628B1 (no)	2004-11-29

Legal Events

Date	Code	Title	Description
1997-08-31	A1OB	Publication of a patent application
1998-04-15	ODBC	Application rejected

Publication	Publication Date	Title
JPH0688912B2 (ja)	1994-11-09	医薬品の局部投与における電流１００μＡ以上のイオン浸透療法に適した経皮流量向上性医薬組成物
EP2281559A1 (de)	2011-02-09	Pharmazeutische Zusammensetzung enthaltend Rotigotin (Salze oder Na), insbesondere für Iontophorese
EP0719138B1 (de)	1999-02-10	Iontophoretische verabreichung eines antimigränemittels
HU184575B (en)	1984-09-28	Method for producing preparations fixable on skin generating locally electrolytic and bio currents
ZA200607105B (en)	2007-12-27	Transdermal iontophoretic delivery of piperazinyl-2(3H)-benzoxazolone compounds
JPWO2007055279A1 (ja)	2009-04-30	イオントフォレーシス用製剤
EP2874693A1 (de)	2015-05-27	Durch ein elektrisches feld unterstützte verabreichung von tapentadol
RU2371179C2 (ru)	2009-10-27	Чрескожное введение соединений пиперазинил-2 (3н)-бензоксазолона посредством электрофореза
Bhat et al.	0	Pharmacology & Pharmacotherapeutics
US20250360156A1 (en)	2025-11-27	Synergistic combination of nad+ and therapeutic peptides delivered via iontophoresis for enhanced and prolonged regenerative effects
JPH0572890B2 (de)	1993-10-13
Madhulatha et al.	2012	Pharmaceutical and Nano Sciences
Kotur	2006	Development Of Atenolol Gels For Transdermal Application By Iontophoresis
JPS6299333A (ja)	1987-05-08	イオントフオレ−ゼ生体電極用基剤組成物
KR20070012432A (ko)	2007-01-25	피페라지닐-2(3ｈ)-벤즈옥사졸론 화합물의 경피이온삼투요법적 전달
WO2005020967A1 (ja)	2005-03-10	電気的薬物移送製剤
MXPA06011018A (en)	2007-04-20	Transdermal iontophoretic delivery of piperazinyl-2(3h)-benzoxazolone compounds